News J&J cuts $3.3bn deal to buy eye drug developer Ollin Johnson & Johnson has agreed to buy Texas biotech Ollin Biosciences for $2.2bn upfront, adding a keenly anticipated therapy for ophthalmic disorders.
News Outlook finally claims FDA approval for AMD drug After three knockbacks by the FDA, Outlook has finally pushed its therapy for age-related macular degeneration over the finish line in the US.
News Bispecific antibody firm Ollin raises $330m in bumper round Ollin has followed its $100m Series A last year with a massive $330m second round that will fund phase 3 trials of its challenger to Roche's Vabysmo.
News Sanofi linked to takeover bid for Ocular Therapeutix Sanofi is reported to be preparing a move to take control of US biotech Ocular Therapeutix, after an initial bid was rejected last year.
News Ocugen shares fall, despite positive eye disorder trial A trial of Ocugen's gene therapy for sight-robbing disease geographic atrophy (GA) showed efficacy – but still sparked a selloff in its shares.
News FDA fast-tracks Sanofi's gene therapy for eye disease GA Sanofi has been granted a speedy review from the FDA for a gene therapy for geographic atrophy, a major cause of blindness.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.